Skin Disorders News

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Alphyn Biologics CEO Neal Koller discusses new data from the company’s phase 2a trial of AB-101a for the treatment of atopic dermatitis.

SAN DIEGO — Researchers found that children with moderate to severe atopic dermatitis have a higher mean weight and BMI, but a lower mean height, than healthy children, according to a poster presented here.

WASHINGTON — Patients with hereditary angioedema experienced reductions in the monthly rate of attacks with lanadelumab, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — While it did not perform at the level of clinicians, ChatGPT could be used as a tool to improve patch testing efficiency for allergic contact dermatitis, according to a poster presentation here.

Babies born during the lockdown of March through May 2020 developed significant differences in their microbiome and less atopic dermatitis compared with babies born prior to this period, according to a study published in Allergy.

WASHINGTON — Patients with chronic spontaneous urticaria experienced better quality of life with dupilumab compared with placebo, according to two posters presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The first patient has been dosed in Jasper Therapeutic’s phase 1b/2a SPOTLIGHT clinical trial of subcutaneous briquilimab for the treatment of chronic inducible urticaria, the company announced in a press release.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — Atopic dermatitis improvement was found with lebrikizumab treatment in patients with skin of color, according to interim study results presented at the American Academy of Dermatology Annual Meeting.